SFDA To Strengthen Electronic Monitoring Of Drugs
This article was originally published in PharmAsia News
By building a national surveillance network on the special drug monitoring platform launched last October, China State FDA will further strengthen electronic drug monitoring by gradually phasing in an electronic identification system. Anesthetics and category 1 psychotropic drugs are already under surveillance, while key pharmaceutical production and circulation companies will be mandated to electronically tag category 2 psychotropic drugs, plasma products, vaccines and TCM injections by Oct. 31. SFDA will draw up a catalog that includes all approved registered drugs to be entered in the surveillance network; firms involved must stick standard electronic codes on their smallest product packs before marketing. Once the electronic network is established, consumers may check on drugs by calling or go online via mobile phones. (Click here for more - Chinese Language)
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.